Compare BAH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAH | IMVT |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.0B |
| IPO Year | 2010 | 2019 |
| Metric | BAH | IMVT |
|---|---|---|
| Price | $71.15 | $38.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $97.00 | $33.00 |
| AVG Volume (30 Days) | ★ 2.4M | 951.3K |
| Earning Date | 05-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $11,217,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $42.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.50 | $14.32 |
| 52 Week High | $114.48 | $41.23 |
| Indicator | BAH | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 50.26 |
| Support Level | $68.84 | $37.53 |
| Resistance Level | $82.96 | $41.22 |
| Average True Range (ATR) | 2.83 | 1.49 |
| MACD | 0.88 | -0.38 |
| Stochastic Oscillator | 63.47 | 36.57 |
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.